Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P3: Long-term Safety and Efficacy of Alpelisib in PROS
NCT04980833Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS), sponsored by Novartis. Primary endpoint: Proportion of participants with new or worsening grade >=3 treatment emergent adverse events (AEs) at 5 years. Started Jan 2022; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT04980833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980833.